April 5, 2023

The U.S. Food and Drug Administration (FDA) released draft guidance — Marketing Submission Recommendations for a Predetermined Change Control Plan (PCCP) for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions — with public comments due July 3.

The document describes information provided by manufacturers that would enable FDA consideration of planned AI/ML software modifications during device marketing submissions. The PCCP enables downstream improvements to AI/ML software functionality without necessitating additional submissions, provided the future modifications are implemented in accordance with the FDA-vetted plan.

The American College of Radiology® (ACR®) is reviewing the draft guidance. Members interested in providing feedback for potential inclusion in ACR’s future comments should contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • ACR Advises Changes to Washington State PAD Report

    ACR urged the WA State Health Technology Clinical Committee to not act on the draft report that would limit coverage of endovascular procedures for PAD.

    Read more
  • ACR Releases Impact Tables for 2026 MPFS Proposed Rule

    The tables cover specific proposed changes in reimbursement rates between 2025 and 2026 for each CPT® code.

    Read more
  • Take Action: Contact Your US Senators to Cosponsor ROOT Act

    Support the ROOT Act—Senate cosponsors needed to fix CMS issues with imaging AUC under PAMA. College member advocacy is key.

    Read more